Fatih Eren

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1497839/publications.pdf

Version: 2024-02-01

304743 330143 1,588 71 22 37 citations h-index g-index papers 74 74 74 2895 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. European Journal of Clinical Investigation, 2010, 40, 887-892.	3.4	159
2	Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2011, 46, 91-97.	1.5	107
3	Role of Ursodeoxycholic Acid in Prevention of Methotrexate-induced Liver Toxicity. Digestive Diseases and Sciences, 2008, 53, 1071-1077.	2.3	99
4	Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2011, 60, 544-549.	3.4	61
5	Rosiglitazone Attenuates Liver Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences, 2007, 52, 3465-3472.	2.3	56
6	Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis, 2011, 217, 125-129.	0.8	53
7	Melatonin ameliorates methionine―and cholineâ€deficient diet―nduced nonalcoholic steatohepatitis in rats. Journal of Pineal Research, 2009, 46, 401-407.	7.4	46
8	The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF- $1\hat{1}$ ± and VEGF. International Journal of Pharmaceutics, 2015, 478, 147-154.	5.2	44
9	Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clinical Biochemistry, 2012, 45, 655-658.	1.9	43
10	A comparison of FibroMeterâ, NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2014, 49, 1343-1348.	1.5	43
11	Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. European Journal of Gastroenterology and Hepatology, 2019, 31, 43-46.	1.6	43
12	The Effects of N-Acetylcysteine on Bile Duct Ligation–Induced Liver Fibrosis in Rats. Digestive Diseases and Sciences, 2007, 52, 3348-3354.	2.3	39
13	Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 631-636.	1.2	39
14	Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 541-546.	1.2	38
15	Local Delivery of Chitosan/VEGF siRNA Nanoplexes Reduces Angiogenesis and Growth of Breast Cancer <i>In Vivo</i> . Nucleic Acid Therapeutics, 2012, 22, 40-48.	3.6	38
16	Iron preloading aggravates nutritional steatohepatitis in rats by increasing apoptotic cell death. Journal of Hepatology, 2007, 47, 851-859.	3.7	37
17	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 936-942.	2.8	37
18	Validation of Risk Scoring Systems in Ursodeoxycholic Acid–Treated Patients With Primary Biliary Cholangitis. American Journal of Gastroenterology, 2019, 114, 1101-1108.	0.4	34

#	Article	IF	Citations
19	Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, 98-103.	1.6	33
20	Serum Levels of Adipokines in Patients with Chronic HCV Infection: Relationship with Steatosis and Fibrosis. Archives of Medical Research, 2009, 40, 294-298.	3.3	28
21	The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. European Journal of Gastroenterology and Hepatology, 2020, 32, 642-649.	1.6	24
22	Serum Progranulin as an Independent Marker of Liver Fibrosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. Disease Markers, 2011, 31, 205-210.	1.3	24
23	Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5. Genetics and Molecular Biology, 2015, 38, 21-29.	1.3	23
24	Top government hands-on megaproject management: the case of Istanbul's grand airport. International Journal of Managing Projects in Business, 2019, 12, 666-693.	2.5	22
25	Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity. Journal of Crohn's and Colitis, 2011, 5, 402-406.	1.3	21
26	Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Digestive and Liver Disease, 2013, 45, 58-62.	0.9	21
27	The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. European Journal of Gastroenterology and Hepatology, 2017, 29, 441-447.	1.6	21
28	Chitosan/Short Hairpin RNA Complexes for Vascular Endothelial Growth Factor Suppression Invasive Breast Carcinoma. Oligonucleotides, 2010, 20, 183-190.	2.7	20
29	Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2012, 47, 1488-1493.	1.5	19
30	Association between bactericidal/permeability increasing protein (BPI) gene polymorphism (Lys216Glu) and inflammatory bowel disease. Journal of Crohn's and Colitis, 2011, 5, 14-18.	1.3	18
31	Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy. Journal of Thrombosis and Thrombolysis, 2011, 32, 59-63.	2.1	18
32	Investigation of the Therapeutic Efficacy of Codelivery of psiRNA–Vascular Endothelial Growth Factor and plL-4 into Chitosan Nanoparticles in the Breast Tumor Model. Journal of Pharmaceutical Sciences, 2014, 103, 785-795.	3.3	17
33	Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clinica Chimica Acta, 2012, 414, 154-157.	1.1	16
34	Familial Mediterranean fever gene (MEFV) mutations and disease severity in systemic lupus erythematosus (SLE): implications for the role of the E148Q MEFV allele in inflammation. Lupus, 2015, 24, 705-711.	1.6	16
35	Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. Clinica Chimica Acta, 2011, 412, 2296-2299.	1.1	14
36	Serum zinc-α2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease. Clinical Chemistry and Laboratory Medicine, 2011, 49, 93-7.	2.3	13

#	Article	IF	CITATIONS
37	Iliac artery perforation and treatment during lumbar disc surgery by simple balloon tamponade. European Spine Journal, 2013, 22, 350-352.	2.2	13
38	Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clinica Chimica Acta, 2010, 411, 2029-2032.	1.1	12
39	The S447X variant of lipoprotein lipase gene is inversely associated with severity of coronary artery disease. Heart and Vessels, 2011, 26, 457-463.	1.2	12
40	R72P Polymorphism of TP53 in Ulcerative Colitis Patients is Associated with the Incidence of Colectomy, Use of Steroids and the Presence of a Positive Family History. Pathology and Oncology Research, 2010, 16, 563-568.	1.9	11
41	The Frequency and the Effects of 21-Hydroxylase Gene Defects in Congenital Adrenal Hyperplasia Patients. Annals of Human Genetics, 2014, 78, 399-409.	0.8	11
42	Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. Clinical Biochemistry, 2011, 44, 955-958.	1.9	10
43	Multi-Locus Candidate Gene Analyses of Lipid Levels in a Pediatric Turkish Cohort: Lessons Learned on< >LPL, CETP, LIPC, ABCA1,< i>and <i>SHBG< i>. OMICS A Journal of Integrative Biology, 2013, 17, 636-645.</i>	2.0	10
44	Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back. Tumori, 2013, 99, 10-16.	1.1	10
45	Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 667-671.	1.6	10
46	Association of ERAP1, IL23R and PTGER4 Polymorphisms with Radiographic Severity of Ankylosing Spondylitis. Open Rheumatology Journal, 2017, 11, 1-9.	0.2	10
47	Effects of lecithin: Cholesterol acyltransferase genotypes, enzyme levels, and activity on high-density lipoprotein levels. Journal of Clinical Lipidology, 2011, 5, 152-158.	1.5	9
48	SHBG Gene Polymorphism (rs1799941) Associates with Metabolic Syndrome in Children and Adolescents. PLoS ONE, 2015, 10, e0116915.	2.5	8
49	Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis. Hormones, 2019, 18, 463-475.	1.9	8
50	Sex hormone binding globulin gene polymorphisms and metabolic syndrome in postmenopausal Turkish women. Cardiology Journal, 2013, 20, 287-293.	1.2	8
51	Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. Annals of Hepatology, 2013, 12, 915-925.	1.5	7
52	A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 1292-1295.	1.6	7
53	Letter: the use of Fibrosisâ€4 score in primary care and diabetology practices—Occam's razor applied to advanced fibrosis screening. Alimentary Pharmacology and Therapeutics, 2020, 52, 1759-1760.	3.7	7
54	The effects of pegylated interferon alpha 2b on bile-duct ligation induced liver fibrosis in rats. Annals of Hepatology, 2009, 8, 234-240.	1.5	6

#	Article	IF	CITATIONS
55	No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects. Turkish Journal of Gastroenterology, 2015, 25, 639-43.	1.1	6
56	Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases. Turkish Journal of Gastroenterology, 2017, 28, 327-328.	1.1	6
57	A Systems Genetics Approach to Dyslipidemia in Children and Adolescents. OMICS A Journal of Integrative Biology, 2015, 19, 248-259.	2.0	5
58	Bactericidal permeability increasing protein gene polymorphism is associated with inflammatory bowel diseases in the Turkish population. Saudi Journal of Gastroenterology, 2015, 21, 239.	1.1	5
59	Effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats. Turkish Journal of Gastroenterology, 2010, 21, 287-292.	1.1	5
60	Evaluation of the Association between Programmed Cell Death-1 Gene Polymorphisms and Hepatocellular Carcinoma Susceptibility in Turkish Subjects. A Pilot Study. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 617-622.	0.9	3
61	Hepatic fibrosis – and not steatosis – is the main determinant of arterial stiffness in non-alcoholic fatty liver disease. Atherosclerosis, 2019, 290, 222-223.	0.8	2
62	Reply to Aydin et al: "To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?― Metabolism: Clinical and Experimental, 2011, 60, e2.	3.4	1
63	NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?. Angiology, 2020, 71, 83-84.	1.8	1
64	Percutaneous antegrade transarterial treatment of traumatic radial arteriovenous fistula. Turk Kardiyoloji Dernegi Arsivi, 2013, 41, 238-240.	0.5	1
65	595 VEGF, BFGF & DOSTATIN DO NOT PREDICT PROGNOSIS IN HEPATOCELLULAR CARSINOMA PATIENTS. Journal of Hepatology, 2010, 52, S234-S235.	3.7	0
66	Epidemiology and Diagnosis of Hepatitis B in the Mediterranean Region and Elsewhere. NATO Science for Peace and Security Series A: Chemistry and Biology, 2010, , 239-260.	0.5	0
67	The Association Between Bactericidal Permeability Increasing Protein (BPI) Gene Polymorphism and Inflammatory Bowel Diseases, Ulcerative Colitis and Crohn's Disease's Subphenotypes. Gastroenterology, 2011, 140, S-484-S-485.	1.3	0
68	Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats. Obesity Surgery, 2011, 21, 1316-1317.	2.1	0
69	Two-year results of primary coronary intervention performed in a medium-scale primary percutaneous coronary intervention center by two cardiologists who are not formally trained in interventional cardiology. Anatolian Journal of Cardiology, 2011, 11, 656-7.	0.4	0
70	Comments on "The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease― Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2019, 29, 548-548.	0.8	0
71	Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter. European Journal of Gastroenterology and Hepatology, 2019, 31, 1601-1602.	1.6	0